

Xandra O Breakefield

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/495722/publications.pdf>

Version: 2024-02-01

319
papers

50,347
citations

2093

100
h-index

1668

214
g-index

320
all docs

320
docs citations

320
times ranked

43124
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	5.5	6,961
2	Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. <i>Nature Cell Biology</i> , 2008, 10, 1470-1476.	4.6	4,285
3	Extracellular vesicles: biology and emerging therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 347-357.	21.5	2,563
4	Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 301-312.	1.7	1,168
5	Extracellular Vesicles: Unique Intercellular Delivery Vehicles. <i>Trends in Cell Biology</i> , 2017, 27, 172-188.	3.6	1,087
6	Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. <i>PLoS Biology</i> , 2012, 10, e1001450.	2.6	1,064
7	The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. <i>Nature Genetics</i> , 1997, 17, 40-48.	9.4	1,051
8	New Technologies for Analysis of Extracellular Vesicles. <i>Chemical Reviews</i> , 2018, 118, 1917-1950.	23.0	1,041
9	RNA delivery by extracellular vesicles in mammalian cells and its applications. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 585-606.	16.1	1,010
10	Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. <i>Nature Communications</i> , 2011, 2, 180.	5.8	974
11	Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. <i>BioScience</i> , 2015, 65, 783-797.	2.2	813
12	Dynamic Biodistribution of Extracellular Vesicles <i>in Vivo</i> Using a Multimodal Imaging Reporter. <i>ACS Nano</i> , 2014, 8, 483-494.	7.3	663
13	Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. <i>Nature Medicine</i> , 2012, 18, 1835-1840.	15.2	647
14	Codon-Optimized Gaussia Luciferase cDNA for Mammalian Gene Expression in Culture and <i>in Vivo</i> . <i>Molecular Therapy</i> , 2005, 11, 435-443.	3.7	635
15	Advances in therapeutic applications of extracellular vesicles. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	595
16	Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. <i>Nature Communications</i> , 2015, 6, 6999.	5.8	484
17	Microfluidic isolation and transcriptome analysis of serum microvesicles. <i>Lab on A Chip</i> , 2010, 10, 505-511.	3.1	462
18	Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. <i>Nature Communications</i> , 2015, 6, 7029.	5.8	449

#	ARTICLE	IF	CITATIONS
19	miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial Cells. <i>Cancer Cell</i> , 2008, 14, 382-393.	7.7	441
20	Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. <i>Nature Genetics</i> , 1995, 9, 152-159.	9.4	430
21	The pathophysiological basis of dystonias. <i>Nature Reviews Neuroscience</i> , 2008, 9, 222-234.	4.9	420
22	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	4.7	416
23	Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 439-464.	4.2	415
24	Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. <i>Nature Communications</i> , 2017, 8, 1145.	5.8	384
25	Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector. <i>Cancer Research</i> , 2006, 66, 2509-2513.	0.4	363
26	Multidimensional communication in the microenvirons of glioblastoma. <i>Nature Reviews Neurology</i> , 2018, 14, 482-495.	4.9	357
27	Extracellular vesicles: emerging targets for cancer therapy. <i>Trends in Molecular Medicine</i> , 2014, 20, 385-393.	3.5	349
28	TorsinA and heat shock proteins act as molecular chaperones: suppression of α -synuclein aggregation. <i>Journal of Neurochemistry</i> , 2002, 83, 846-854.	2.1	318
29	Viral vectors for gene delivery to the nervous system. <i>Nature Reviews Neuroscience</i> , 2003, 4, 353-364.	4.9	292
30	BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e109.	2.3	284
31	Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth. <i>Molecular Therapy</i> , 2013, 21, 101-108.	3.7	282
32	miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development. <i>PLoS ONE</i> , 2013, 8, e78115.	1.1	270
33	A secreted luciferase for ex vivo monitoring of in vivo processes. <i>Nature Methods</i> , 2008, 5, 171-173.	9.0	263
34	SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. <i>Science</i> , 2016, 352, 242-246.	6.0	259
35	High levels of AAV vector integration into CRISPR-induced DNA breaks. <i>Nature Communications</i> , 2019, 10, 4439.	5.8	257
36	Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. <i>NeuroReport</i> , 1993, 4, 367-370.	0.6	256

#	ARTICLE	IF	CITATIONS
37	Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano, 2018, 12, 494-503.	7.3	256
38	Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nature Communications, 2018, 9, 175.	5.8	248
39	Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype. Annals of Neurology, 2000, 48, 65-71.	2.8	247
40	Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron, 1989, 2, 1427-1434.	3.8	246
41	Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro-Oncology, 2016, 18, 58-69.	0.6	245
42	Downregulated MicroRNA-200a in Meningiomas Promotes Tumor Growth by Reducing E-Cadherin and Activating the Wnt/ β -Catenin Signaling Pathway. Molecular and Cellular Biology, 2009, 29, 5923-5940.	1.1	240
43	Microvesicle-associated AAV Vector as a Novel Gene Delivery System. Molecular Therapy, 2012, 20, 960-971.	3.7	236
44	miR-1289 and "Zipcode"-like Sequence Enrich mRNAs in Microvesicles. Molecular Therapy - Nucleic Acids, 2012, 1, e10.	2.3	235
45	From The Cover: TorsinA in the nuclear envelope. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7612-7617.	3.3	225
46	Emerging Roles of Extracellular Vesicles in the Nervous System. Journal of Neuroscience, 2014, 34, 15482-15489.	1.7	219
47	Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. Cell, 2019, 177, 446-462.e16.	13.5	214
48	In Vivo Tracking of Neural Progenitor Cell Migration to Glioblastomas. Human Gene Therapy, 2003, 14, 1247-1254.	1.4	210
49	Herpes Simplex Virus Type 1 DNA Amplified as Bacterial Artificial Chromosome in <i>Escherichia coli</i> : Rescue of Replication-Competent Virus Progeny and Packaging of Amplicon Vectors. Human Gene Therapy, 1998, 9, 2787-2794.	1.4	209
50	Improved Helper Virus-Free Packaging System for HSV Amplicon Vectors Using an ICP27-Deleted, Oversized HSV-1 DNA in a Bacterial Artificial Chromosome. Molecular Therapy, 2001, 3, 591-601.	3.7	200
51	Prodrug activation enzymes in cancer gene therapy. Journal of Gene Medicine, 2000, 2, 148-164.	1.4	191
52	Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Human Molecular Genetics, 2000, 9, 1403-1413.	1.4	190
53	Clioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology, 2005, 57, 34-41.	2.8	188
54	Extracellular vesicles and intercellular communication within the nervous system. Journal of Clinical Investigation, 2016, 126, 1198-1207.	3.9	188

#	ARTICLE	IF	CITATIONS
55	Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. <i>Molecular Therapy</i> , 2017, 25, 379-391.	3.7	181
56	Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation. <i>Annals of Neurology</i> , 1994, 36, 771-777.	2.8	176
57	RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. <i>BMC Cancer</i> , 2012, 12, 22.	1.1	176
58	Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. <i>Neuro-Oncology</i> , 2017, 19, 1494-1502.	0.6	168
59	Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. <i>Cell</i> , 2018, 172, 897-909.e21.	13.5	163
60	Intravascular Delivery of Neural Stem Cell Lines to Target Intracranial and Extracranial Tumors of Neural and Non-Neural Origin. <i>Human Gene Therapy</i> , 2003, 14, 1777-1785.	1.4	162
61	Gene Transfer into Experimental Brain Tumors Mediated by Adenovirus, Herpes Simplex Virus, and Retrovirus Vectors. <i>Human Gene Therapy</i> , 1994, 5, 183-191.	1.4	160
62	TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. <i>Journal of Cell Science</i> , 2008, 121, 3476-3486.	1.2	159
63	Heparin blocks transfer of extracellular vesicles between donor and recipient cells. <i>Journal of Neuro-Oncology</i> , 2013, 115, 343-351.	1.4	156
64	Novel mutation in the TOR1A (DYT1) gene in atypical, early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. <i>Neurogenetics</i> , 2001, 3, 133-143.	0.7	155
65	Heparin affinity purification of extracellular vesicles. <i>Scientific Reports</i> , 2015, 5, 10266.	1.6	152
66	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019, 177, 231-242.	13.5	152
67	Neural Precursor Cells for Delivery of Replication-Conditional HSV-1 Vectors to Intracerebral Gliomas. <i>Molecular Therapy</i> , 2000, 1, 347-357.	3.7	151
68	FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. <i>Journal of Clinical Investigation</i> , 2003, 112, 1202-1210.	3.9	151
69	Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. <i>Nature Genetics</i> , 1993, 4, 160-164.	9.4	149
70	TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. <i>Neurobiology of Disease</i> , 2003, 12, 11-24.	2.1	148
71	Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. <i>Annals of Neurology</i> , 2002, 51, 621-625.	2.8	147
72	HSV/AAV Hybrid Amplicon Vectors Extend Transgene Expression in Human Glioma Cells. <i>Human Gene Therapy</i> , 1997, 8, 359-370.	1.4	146

#	ARTICLE	IF	CITATIONS
73	Experimental Tumor Therapy in Mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 Gene. <i>Human Gene Therapy</i> , 1994, 5, 969-978.	1.4	144
74	Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. <i>Brain Research</i> , 1995, 691, 25-36.	1.1	143
75	The TOR1A (DYT1) Gene Family and Its Role in Early Onset Torsion Dystonia. <i>Genomics</i> , 1999, 62, 377-384.	1.3	142
76	miRNA-7 Attenuation in Schwannoma Tumors Stimulates Growth by Upregulating Three Oncogenic Signaling Pathways. <i>Cancer Research</i> , 2011, 71, 852-861.	0.4	142
77	Glioblastoma-Associated Microglia Reprogramming Is Mediated by Functional Transfer of Extracellular miR-21. <i>Cell Reports</i> , 2019, 28, 3105-3119.e7.	2.9	142
78	Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34. <i>Annals of Neurology</i> , 1990, 27, 114-120.	2.8	141
79	TorsinA. <i>Neuron</i> , 2001, 31, 9-12.	3.8	136
80	Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. <i>Annals of Neurology</i> , 1999, 46, 761-769.	2.8	135
81	Impaired Motor Learning in Mice Expressing TorsinA with the DYT1 Dystonia Mutation. <i>Journal of Neuroscience</i> , 2005, 25, 5351-5355.	1.7	134
82	Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates. <i>American Journal of Human Genetics</i> , 2004, 74, 1064-1073.	2.6	133
83	An experimental model of retrovirus gene therapy for malignant brain tumors. <i>Journal of Neurosurgery</i> , 1993, 79, 104-110.	0.9	132
84	Viral vectors for therapy of neurologic diseases. <i>Neuropharmacology</i> , 2017, 120, 63-80.	2.0	130
85	Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. <i>Cellular and Molecular Neurobiology</i> , 1993, 13, 503-515.	1.7	128
86	Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. <i>Oncogene</i> , 2003, 22, 6865-6872.	2.6	128
87	Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 7271-7276.	3.3	127
88	A Highly Sensitive Assay for Monitoring the Secretory Pathway and ER Stress. <i>PLoS ONE</i> , 2007, 2, e571.	1.1	123
89	Structural Features of Human Monoamine Oxidase A Elucidated from cDNA and Peptide Sequences. <i>Journal of Neurochemistry</i> , 1988, 51, 1321-1324.	2.1	118
90	Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in <i>TAF1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E11020-E11028.	3.3	118

#	ARTICLE	IF	CITATIONS
91	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 429-440.	2.3	116
92	Expression of the early-onset torsion dystonia gene (DYT1) in human brain. <i>Annals of Neurology</i> , 1998, 43, 669-673.	2.8	111
93	TorsinA in PC12 cells: Localization in the endoplasmic reticulum and response to stress. <i>Journal of Neuroscience Research</i> , 2003, 72, 158-168.	1.3	111
94	Dopamine release is impaired in a mouse model of DYT1 dystonia. <i>Journal of Neurochemistry</i> , 2007, 102, 783-788.	2.1	111
95	Extracellular Vesicles and Their Convergence with Viral Pathways. <i>Advances in Virology</i> , 2012, 2012, 1-12.	0.5	111
96	A Close Association of TorsinA and α -Synuclein in Lewy Bodies. <i>American Journal of Pathology</i> , 2001, 159, 339-344.	1.9	110
97	Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. <i>Journal of Neurosurgery</i> , 1993, 78, 267-273.	0.9	109
98	Functional Coexpression of HSV-1 Thymidine Kinase and Green Fluorescent Protein: Implications for Noninvasive Imaging of Transgene Expression. <i>Neoplasia</i> , 1999, 1, 154-161.	2.3	109
99	Differences in A and B forms of monoamine oxidase revealed by limited proteolysis and peptide mapping. <i>Nature</i> , 1979, 281, 692-694.	13.7	108
100	In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. <i>Molecular Therapy</i> , 2005, 11, 926-931.	3.7	105
101	Metabolic biotinylation of cell surface receptors for in vivo imaging. <i>Nature Methods</i> , 2006, 3, 391-396.	9.0	105
102	Glioma-Derived miRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells. <i>Cell Reports</i> , 2020, 30, 2065-2074.e4.	2.9	105
103	Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier. <i>Human Molecular Genetics</i> , 2006, 15, 1355-1364.	1.4	104
104	Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. <i>Neurobiology of Disease</i> , 2006, 22, 98-111.	2.1	103
105	Human monoamine oxidase gene (MAOA): Chromosome position (Xp21-p11) and DNA polymorphism. <i>Genomics</i> , 1988, 3, 53-58.	1.3	102
106	A Novel Method for Imaging Apoptosis Using a Caspase-1 Near-Infrared Fluorescent Probe. <i>Neoplasia</i> , 2004, 6, 95-105.	2.3	101
107	Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. <i>Hearing Research</i> , 1999, 134, 1-8.	0.9	99
108	Critical Issues in Gene Therapy for Neurologic Disease. <i>Human Gene Therapy</i> , 2002, 13, 579-604.	1.4	99

#	ARTICLE	IF	CITATIONS
109	TorsinA participates in endoplasmic reticulum-associated degradation. <i>Nature Communications</i> , 2011, 2, 393.	5.8	99
110	Bimodal Viral Vectors and <i>In Vivo</i> Imaging Reveal the Fate of Human Neural Stem Cells in Experimental Glioma Model. <i>Journal of Neuroscience</i> , 2008, 28, 4406-4413.	1.7	98
111	Rapid-onset dystonia-parkinsonism: Linkage to chromosome 19q13. <i>Annals of Neurology</i> , 1999, 46, 176-182.	2.8	97
112	Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2. <i>PLoS ONE</i> , 2011, 6, e16282.	1.1	96
113	Gene Therapy for Brain Tumors. <i>Brain Pathology</i> , 1995, 5, 345-381.	2.1	93
114	Brain Tumor Microvesicles: Insights into Intercellular Communication in the Nervous System. <i>Cellular and Molecular Neurobiology</i> , 2011, 31, 949-959.	1.7	93
115	The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. <i>Human Molecular Genetics</i> , 2010, 19, 3502-3515.	1.4	92
116	Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy. <i>Cancer Research</i> , 2004, 64, 3236-3242.	0.4	91
117	Differences in the Structure of A and B Forms of Human Monoamine Oxidase. <i>Journal of Neurochemistry</i> , 1981, 37, 363-372.	2.1	90
118	HSV-1 Amplicon Vectors—Simplicity and Versatility. <i>Molecular Therapy</i> , 2000, 2, 9-15.	3.7	88
119	Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 417-427.	1.7	87
120	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1588555.	5.5	86
121	Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. <i>Cancer Research</i> , 2016, 76, 2876-2881.	0.4	85
122	Genetically modified fibroblasts producing NGF protect hippocampal neurons after ischemia in the rat. <i>NeuroReport</i> , 1995, 6, 669-672.	0.6	82
123	Molecular pathways in dystonia. <i>Neurobiology of Disease</i> , 2011, 42, 136-147.	2.1	81
124	Îµ-sarcoglycan mutations found in combination with other dystonia gene mutations. <i>Annals of Neurology</i> , 2002, 52, 675-679.	2.8	80
125	The Early Onset Dystonia Protein TorsinA Interacts with Kinesin Light Chain 1. <i>Journal of Biological Chemistry</i> , 2004, 279, 19882-19892.	1.6	80
126	Molecular Genetics of the Monoamine Oxidases. <i>Journal of Neurochemistry</i> , 1989, 53, 12-18.	2.1	79

#	ARTICLE	IF	CITATIONS
127	Secretion and Uptake of α -Synuclein Via Extracellular Vesicles in Cultured Cells. <i>Cellular and Molecular Neurobiology</i> , 2018, 38, 1539-1550.	1.7	79
128	Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. <i>Movement Disorders</i> , 1994, 9, 305-310.	2.2	75
129	Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 459-470.	1.7	75
130	Mutations in the Norrie disease gene. <i>Human Mutation</i> , 1995, 5, 285-292.	1.1	74
131	Single-Step Conversion of Cells to Retrovirus Vector Producers with Herpes Simplex Virus- α 1 Epstein-Barr Virus Hybrid Amplicons. <i>Journal of Virology</i> , 1999, 73, 10426-10439.	1.5	74
132	Characterization of single microvesicles in plasma from glioblastoma patients. <i>Neuro-Oncology</i> , 2019, 21, 606-615.	0.6	72
133	Glioblastoma hijacks microglial gene expression to support tumor growth. <i>Journal of Neuroinflammation</i> , 2020, 17, 120.	3.1	71
134	Gene Therapy for the Nervous System: Challenges and New Strategies. <i>Neurotherapeutics</i> , 2014, 11, 817-839.	2.1	70
135	New Prodrug Activation Gene Therapy for Cancer Using Cytochrome P450 4B1 and 2-Aminoanthracene/4-Ipomeanol. <i>Human Gene Therapy</i> , 1998, 9, 1261-1273.	1.4	69
136	Precise Genetic Mapping and Haplotype Analysis of the Familial Dysautonomia Gene on Human Chromosome 9q31. <i>American Journal of Human Genetics</i> , 1999, 64, 1110-1118.	2.6	69
137	Soluble and Particulate Forms of Rat Catechol-O-Methyltransferase Distinguished by Gel Electrophoresis and Immune Fixation. <i>Journal of Neurochemistry</i> , 1985, 44, 421-432.	2.1	68
138	Benefits and risks of hosting animal cells in the human brain. <i>Nature Medicine</i> , 1997, 3, 964-969.	15.2	68
139	Selective Uptake of Viral and Monocrystalline Particles Delivered Intra-Arterially to Experimental Brain Neoplasms. <i>Human Gene Therapy</i> , 1995, 6, 1543-1552.	1.4	67
140	Fine Localization of the Torsion Dystonia Gene (<i>DYT1</i>) on Human Chromosome 9q34: YAC Map and Linkage Disequilibrium. <i>Genome Research</i> , 1997, 7, 483-494.	2.4	67
141	Extracellular RNA mediates and marks cancer progression. <i>Seminars in Cancer Biology</i> , 2014, 28, 14-23.	4.3	67
142	Structure of the human gene for monoamine oxidase type A. <i>Nucleic Acids Research</i> , 1991, 19, 4537-4541.	6.5	66
143	Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir Treatment. <i>Human Gene Therapy</i> , 1996, 7, 1989-1994.	1.4	66
144	Genetic Testing for Early-Onset Torsion Dystonia (<i>DYT1</i>): Introduction of a Simple Screening Method, Experiences from Testing of a Large Patient Cohort, and Ethical Aspects. <i>Genetic Testing and Molecular Biomarkers</i> , 1999, 3, 323-328.	1.7	66

#	ARTICLE	IF	CITATIONS
145	Uptake, functionality, and re-release of extracellular vesicle-encapsulated cargo. <i>Cell Reports</i> , 2022, 39, 110651.	2.9	64
146	Mapping the <i>In Vivo</i> Distribution of Herpes Simplex Virions. <i>Human Gene Therapy</i> , 1998, 9, 1543-1549.	1.4	63
147	Update on herpesvirus amplicon vectors. <i>Molecular Therapy</i> , 2004, 10, 630-643.	3.7	63
148	siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. <i>Human Molecular Genetics</i> , 2008, 17, 1436-1445.	1.4	63
149	Genetic therapy for the nervous system. <i>Human Molecular Genetics</i> , 2011, 20, R28-R41.	1.4	62
150	HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part II. Vector Systems and Applications. <i>Neoplasia</i> , 1999, 1, 402-416.	2.3	61
151	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 225-235.	0.6	61
152	Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus. <i>Current Gene Therapy</i> , 2004, 4, 385-408.	0.9	61
153	Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. <i>Brain Research</i> , 2003, 986, 12-21.	1.1	60
154	Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease. <i>Brain Research</i> , 1994, 658, 219-231.	1.1	59
155	Glial growth factor-like activity in Schwann cell tumors. <i>Annals of Neurology</i> , 1986, 20, 317-322.	2.8	58
156	Monoamine oxidases A and B are differentially regulated by glucocorticoids and aging in human skin fibroblasts. <i>Cellular and Molecular Neurobiology</i> , 1986, 6, 121-150.	1.7	57
157	Large and small extracellular vesicles released by glioma cells <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1689784.	5.5	57
158	Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3693-3703.	3.3	57
159	Receptor Binding Activities of Biotinylated Derivatives of Nerve Growth Factor. <i>Journal of Neurochemistry</i> , 1986, 46, 641-648.	2.1	56
160	Live Visualization of Herpes Simplex Virus Type 1 Compartment Dynamics. <i>Journal of Virology</i> , 2008, 82, 4974-4990.	1.5	55
161	Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 386-396.	1.2	55
162	Properties of monoamine oxidase in control and Lesch-Nyhan fibroblasts. <i>Biochemical Genetics</i> , 1980, 18, 577-590.	0.8	54

#	ARTICLE	IF	CITATIONS
163	Specificity of antisera prepared against pure bovine MAO-B. <i>Brain Research</i> , 1983, 276, 127-139.	1.1	53
164	±-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 437-448.	1.7	53
165	Search for a Founder Mutation in Idiopathic Focal Dystonia from Northern Germany. <i>American Journal of Human Genetics</i> , 1998, 63, 1777-1782.	2.6	52
166	Intraarterial Delivery of Adenovirus Vectors and Liposome-DNA Complexes to Experimental Brain Neoplasms. <i>Human Gene Therapy</i> , 1999, 10, 311-318.	1.4	51
167	In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced Gliomas. <i>Cancer Research</i> , 2004, 64, 273-278.	0.4	51
168	Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26533.	5.5	51
169	Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy. <i>Molecular Therapy</i> , 2015, 23, 824-834.	3.7	51
170	Developmental patterns of torsinA and torsinB expression. <i>Brain Research</i> , 2006, 1073-1074, 139-145.	1.1	47
171	Temperature-Sensitive Divisionless Mutant of <i>Bacillus subtilis</i> Defective in the Initiation of Septation. <i>Journal of Bacteriology</i> , 1973, 113, 985-998.	1.0	47
172	Monoamine oxidase and catechol-O-methyltransferase activities in cultured human skin fibroblasts. <i>Life Sciences</i> , 1976, 19, 1705-1710.	2.0	46
173	MONOAMINE OXIDASE A AND B IN CULTURED CELLS. <i>Journal of Neurochemistry</i> , 1978, 30, 1391-1397.	2.1	46
174	Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. <i>Cancer Gene Therapy</i> , 2001, 8, 506-511.	2.2	45
175	MONOAMINE OXIDASE ACTIVITY IN NORMAL and LESCH-NYHAN FIBROBLASTS. <i>Journal of Neurochemistry</i> , 1978, 31, 1247-1254.	2.1	44
176	Monoamine oxidase type a in fibroblasts from patients with bipolar depressive illness. <i>Psychiatry Research</i> , 1980, 2, 307-314.	1.7	42
177	Gesicles: Microvesicle "Cookies" for Transient Information Transfer Between Cells. <i>Molecular Therapy</i> , 2011, 19, 1574-1576.	3.7	42
178	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. <i>Annals of Neurology</i> , 2000, 47, 369-373.	2.8	41
179	HSV-1 Virions Engineered for Specific Binding to Cell Surface Receptors. <i>Molecular Therapy</i> , 2004, 9, 419-427.	3.7	41
180	Extracellular Vesicle-Mediated Bilateral Communication between Glioblastoma and Astrocytes. <i>Trends in Neurosciences</i> , 2021, 44, 215-226.	4.2	41

#	ARTICLE	IF	CITATIONS
181	Uptake and binding of dopamine and 6-hydroxydopamine in murine neuroblastoma and fibroblast cells. <i>Biochemical Pharmacology</i> , 1976, 25, 383-388.	2.0	39
182	Preventing Growth of Brain Tumors by Creating a Zone of Resistance. <i>Molecular Therapy</i> , 2008, 16, 1695-1702.	3.7	39
183	Noninvasive In Vivo Monitoring of Extracellular Vesicles. <i>Methods in Molecular Biology</i> , 2014, 1098, 249-258.	0.4	39
184	A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. <i>Neurogenetics</i> , 2003, 4, 199-205.	0.7	38
185	TorsinB - perinuclear location and association with torsinA. <i>Journal of Neurochemistry</i> , 2004, 89, 1186-1194.	2.1	38
186	Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. <i>Nature Communications</i> , 2018, 9, 3906.	5.8	38
187	Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. <i>Cell Reports</i> , 2019, 27, 255-268.e6.	2.9	38
188	Genetics of Primary Dystonia. <i>Seminars in Neurology</i> , 1999, 19, 271-280.	0.5	37
189	Clinical and genetic evaluation of a family with a mixed dystonia phenotype from south tyrol. <i>Annals of Neurology</i> , 1998, 44, 394-398.	2.8	36
190	Treatment of Schwannomas with an Oncolytic Recombinant Herpes Simplex Virus in Murine Models of Neurofibromatosis Type 2. <i>Human Gene Therapy</i> , 2006, 17, 20-30.	1.4	36
191	Decreased N-TAF1 expression in X-Linked Dystonia-Parkinsonism patient-specific neural stem cells. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 451-62.	1.2	36
192	HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part I. HSV-1 Structure, Replication and Pathogenesis. <i>Neoplasia</i> , 1999, 1, 387-401.	2.3	35
193	Monoamine oxidase (MAO) activity as a determinant in human neurophysiology. <i>Behavior Genetics</i> , 1982, 12, 53-68.	1.4	34
194	A Novel "Piggyback"™ Packaging System for Herpes Simplex Virus Amplicon Vectors. <i>Human Gene Therapy</i> , 1996, 7, 2003-2013.	1.4	34
195	Neurotransmitter metabolism in murine neuroblastoma cells. <i>Life Sciences</i> , 1976, 18, 267-278.	2.0	33
196	Monoamine oxidase and catechol-o-methyltransferase activities in cultured fibroblasts and blood cells from children with autism and the Gilles de la Tourette syndrome. <i>Psychiatry Research</i> , 1980, 2, 187-197.	1.7	33
197	Targeted Integration of Functional Human ATM cDNA Into Genome Mediated by HSV/AAV Hybrid Amplicon Vector. <i>Molecular Therapy</i> , 2008, 16, 81-88.	3.7	33
198	β-Galactosidase Gene Mutations in Patients With Slowly Progressive GM1 Gangliosidosis. <i>Journal of Child Neurology</i> , 1997, 12, 242-247.	0.7	32

#	ARTICLE	IF	CITATIONS
199	Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells. <i>Neuro-Oncology</i> , 2016, 18, now099.	0.6	32
200	Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women. <i>Cell Reports Medicine</i> , 2020, 1, 100013.	3.3	32
201	Authentic and artifactual detection of the <i>E. coli lacZ</i> gene product in the rat brain by histochemical methods. <i>Molecular Brain Research</i> , 1992, 16, 311-315.	2.5	31
202	Herpes Vector-Mediated Delivery of Marker Genes to Disseminated Central Nervous System Tumors. <i>Human Gene Therapy</i> , 1996, 7, 291-300.	1.4	31
203	Inhibition of N-linked glycosylation prevents inclusion formation by the dystonia-related mutant form of torsinA. <i>Molecular and Cellular Neurosciences</i> , 2004, 27, 417-426.	1.0	30
204	Relationship Between Platelet Monoamine Oxidase B Activity and Alleles at the MAOB Locus. <i>Journal of Neurochemistry</i> , 1992, 59, 2063-2066.	2.1	30
205	Mutational analysis of the human MAOA gene. , 1996, 67, 92-97.		29
206	Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. <i>Cancer Gene Therapy</i> , 1999, 6, 14-20.	2.2	29
207	Localized catecholamine storage associated with granules in murine neuroblastoma cells. <i>Brain Research</i> , 1975, 92, 237-256.	1.1	28
208	THE CATECHOL ESTROGEN, 2-HYDROXYESTRADIOL, INHIBITS CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN NEUROBLASTOMA CELLS. <i>Journal of Neurochemistry</i> , 1978, 31, 245-250.	2.1	28
209	Herpes Simplex Virus Type 1 Amplicon Vector-Mediated Gene Transfer to Muscle. <i>Human Gene Therapy</i> , 2002, 13, 261-273.	1.4	28
210	In vivo tomographic imaging of red-shifted fluorescent proteins. <i>Biomedical Optics Express</i> , 2011, 2, 887.	1.5	28
211	Screen for MAOA mutations in target human groups. <i>American Journal of Medical Genetics Part A</i> , 1999, 88, 25-28.	2.4	27
212	Hybrid vector designs to control the delivery, fate and expression of transgenes. <i>Journal of Gene Medicine</i> , 2000, 2, 395-408.	1.4	27
213	Phenotypic variability in a large kindred (Family LA) with deletions in the parkin gene. <i>Movement Disorders</i> , 2002, 17, 424-426.	2.2	27
214	LONG-TERM EXPRESSION OF THE GENE ENCODING GREEN FLUORESCENT PROTEIN IN MURINE HEMATOPOIETIC CELLS USING RETROVIRAL GENE TRANSFER1. <i>Transplantation</i> , 1998, 65, 1233-1240.	0.5	27
215	Targeting of Liposomes to Cells Bearing Nerve Growth Factor Receptors Mediated by Biotinylated Nerve Growth Factor. <i>Journal of Neurochemistry</i> , 1987, 48, 865-875.	2.1	26
216	Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. <i>Journal of Neuroscience Methods</i> , 2002, 121, 211-219.	1.3	26

#	ARTICLE	IF	CITATIONS
217	New insights and updated guidelines for epigenome-wide association studies. <i>Neuroepigenetics</i> , 2015, 1, 14-19.	2.8	26
218	Dopamine transmission in DYT1 dystonia. <i>Advances in Neurology</i> , 2004, 94, 53-60.	0.8	26
219	Dexamethasone selectively increases monoamine oxidase type a in human skin fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1981, 98, 836-843.	1.0	25
220	Differences in the structures of monoamine oxidases A and B in rat clonal cell lines. <i>Biochemical Pharmacology</i> , 1983, 32, 441-448.	2.0	25
221	Biochemical and Cellular Analysis of Human Variants of the DYT1 Dystonia Protein, TorsinA/TOR1A. <i>Human Mutation</i> , 2014, 35, 1101-1113.	1.1	25
222	Linkage Analysis in a Family with Dominantly Inherited Torsion Dystonia: Exclusion of the Pro-Opiomelanocortin and Glutamic Acid Decarboxylase Genes and Other Chromosomal Regions Using DNA Polymorphisms. <i>Journal of Neurogenetics</i> , 1986, 3, 159-175.	0.6	24
223	Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. <i>Molecular Therapy</i> , 2003, 7, 790-800.	3.7	24
224	Gene transfer into the nervous system. <i>Molecular Neurobiology</i> , 1987, 1, 339-371.	1.9	23
225	Targeting gene therapy vectors to CNS malignancies. <i>Journal of NeuroVirology</i> , 1998, 4, 133-147.	1.0	23
226	Potentiated Gene Delivery to Tumors Using Herpes Simplex Virus/Epstein-Barr Virus/RV Tribrid Amplicon Vectors. <i>Human Gene Therapy</i> , 2003, 14, 611-626.	1.4	23
227	Untethering the Nuclear Envelope and Cytoskeleton: Biologically Distinct Dystonias Arising from a Common Cellular Dysfunction. <i>International Journal of Cell Biology</i> , 2012, 2012, 1-18.	1.0	23
228	Neural Precursor Cells and Their Role in Neuro-Oncology. <i>Developmental Neuroscience</i> , 2004, 26, 118-130.	1.0	22
229	Animal models for drug discovery in dystonia. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 83-97.	2.5	22
230	dtorsin, the Drosophila Ortholog of the Early-Onset Dystonia TOR1A (DYT1), Plays a Novel Role in Dopamine Metabolism. <i>PLoS ONE</i> , 2011, 6, e26183.	1.1	22
231	Glioma EVs Contribute to Immune Privilege in the Brain. <i>Trends in Cancer</i> , 2019, 5, 393-396.	3.8	22
232	Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. <i>Journal of Neurosurgery</i> , 1997, 87, 89-95.	0.9	21
233	RNAi blocks DYT1 mutant torsinA inclusions in neurons. <i>Neuroscience Letters</i> , 2006, 395, 201-205.	1.0	21
234	Regression of Schwannomas Induced by Adeno-Associated Virus-Mediated Delivery of Caspase-1. <i>Human Gene Therapy</i> , 2013, 24, 152-162.	1.4	21

#	ARTICLE	IF	CITATIONS
235	RESERPINE SENSITIVITY OF CATECHOLAMINE METABOLISM IN MURINE NEUROBLASTOMA CLONE N1E-115. <i>Journal of Neurochemistry</i> , 1975, 25, 877-882.	2.1	20
236	Combining CNS transplantation and gene transfer. <i>Neurobiology of Aging</i> , 1989, 10, 647-648.	1.5	20
237	The role of "tumor suppressor"™ genes in neural tumors. <i>Trends in Neurosciences</i> , 1990, 13, 3-6.	4.2	20
238	A genetic linkage map of human chromosome 9q. <i>Genomics</i> , 1992, 14, 715-720.	1.3	20
239	Dynamics of Transgene Expression in Human Glioblastoma Cells Mediated by Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors. <i>Human Gene Therapy</i> , 2002, 13, 2147-2159.	1.4	20
240	miRNA signature of schwannomas: Possible role(s) of "tumor suppressor"•miRNAs in benign tumors. <i>Oncotarget</i> , 2011, 2, 265-270.	0.8	20
241	Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. <i>Journal of Gene Medicine</i> , 1999, 1, 176-185.	1.4	19
242	HSV Amplicon Vectors for Cancer Therapy. <i>Current Gene Therapy</i> , 2006, 6, 361-370.	0.9	19
243	Mutant Sodium Channel for Tumor Therapy. <i>Molecular Therapy</i> , 2009, 17, 810-819.	3.7	18
244	TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-linked Dystonia•Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 206-215.	2.2	18
245	[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. <i>Movement Disorders</i> , 2002, 17, 789-794.	2.2	17
246	Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 18-26.	1.8	17
247	Membrane-bound Gaussia luciferase as a tool to track shedding of membrane proteins from the surface of extracellular vesicles. <i>Scientific Reports</i> , 2019, 9, 17387.	1.6	17
248	Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. <i>Science Advances</i> , 2021, 7, .	4.7	17
249	Tyrosine-dependent increase of tyrosine hydroxylase in neuroblastoma cells. <i>Nature</i> , 1974, 252, 719-720.	13.7	16
250	Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat. <i>Molecular Brain Research</i> , 2002, 101, 132-135.	2.5	16
251	Stochastic Model of Tsc1 Lesions in Mouse Brain. <i>PLoS ONE</i> , 2013, 8, e64224.	1.1	16
252	High-Affinity [3H]Choline Accumulation in Cultured Human Skin Fibroblasts. <i>Journal of Neurochemistry</i> , 1981, 36, 746-752.	2.1	15

#	ARTICLE	IF	CITATIONS
253	The Autosomal Dominant Dystonias. <i>Brain Pathology</i> , 1992, 2, 297-308.	2.1	15
254	A novel imaging-compatible sciatic nerve schwannoma model. <i>Journal of Neuroscience Methods</i> , 2011, 195, 75-77.	1.3	15
255	New methods for investigation of neuronal migration in embryonic brain explants. <i>Journal of Neuroscience Methods</i> , 2015, 239, 80-84.	1.3	15
256	A comparison of the proliferative and replicative life span kinetics of cell cultures derived from monozygotic twins. <i>In Vitro</i> , 1981, 17, 20-27.	1.2	14
257	Correction of Acidbeta-Galactosidase Deficiency in GM1Gangliosidosis Human Fibroblasts by Retrovirus VectorMediated Gene Transfer: Higher Efficiency of Release and Cross-Correction by the Murine Enzyme. <i>Human Gene Therapy</i> , 2000, 11, 715-727.	1.4	14
258	Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. <i>Neurobiology of Disease</i> , 2015, 82, 22-31.	2.1	14
259	CRISPR-Cas knockout of miR21 reduces glioma growth. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 121-136.	2.0	14
260	TRANSPORT OF TYROSINE, PHENYLALANINE, TRYPTOPHAN AND GLYCINE IN NEUROBLASTOMA CLONES. <i>Journal of Neurochemistry</i> , 1977, 28, 127-135.	2.1	13
261	Catechol-O-methyltransferase activity in cultured human skin fibroblasts from controls and patients with dystonia musculorum deformans. <i>Journal of Neuroscience Research</i> , 1981, 6, 349-360.	1.3	13
262	Characterization of monoamine oxidase activity during early stages of quail embryogenesis. <i>International Journal of Developmental Neuroscience</i> , 1983, 1, 49-57.	0.7	13
263	HSV-1 amplicon peptide display vector. <i>Journal of Virological Methods</i> , 2003, 107, 71-79.	1.0	13
264	Microfluidic platform to evaluate migration of cells from patients with DYT1 dystonia. <i>Journal of Neuroscience Methods</i> , 2014, 232, 181-188.	1.3	13
265	Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo. <i>Biomaterials</i> , 2022, 281, 121366.	5.7	13
266	Phenylalanine hydroxylase in melanoma cells. <i>Journal of Cellular Physiology</i> , 1978, 94, 307-314.	2.0	12
267	Artifactual presence of β -nerve growth factor in adult mouse brain. <i>Brain Research</i> , 1984, 295, 35-40.	1.1	12
268	Co-factor insufficiency in Dystonia-Parkinsonian syndrome. <i>Nature Genetics</i> , 1994, 8, 207-208.	9.4	12
269	Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases. <i>Molecular Therapy</i> , 2013, 21, 266-268.	3.7	12
270	Living Proof of Activity of Extracellular Vesicles in the Central Nervous System. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7294.	1.8	12

#	ARTICLE	IF	CITATIONS
271	Neurotransmitter metabolism in cell culture. <i>Biochemical Pharmacology</i> , 1976, 25, 2337-2342.	2.0	11
272	The human gene for neurotrophic tyrosine kinase receptor type 2 (NTRK2) is located on chromosome 9 but is not the familial dysautonomia gene. <i>Genomics</i> , 1995, 25, 730-732.	1.3	11
273	[34] HSV-1 amplicon vectors. <i>Methods in Enzymology</i> , 2002, 346, 593-603.	0.4	11
274	Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. <i>Movement Disorders</i> , 2004, 19, 845-847.	2.2	11
275	Exosome/microvesicle content is altered in leucine-rich repeat kinase 2 mutant induced pluripotent stem cell-derived neural cells. <i>Journal of Comparative Neurology</i> , 2020, 528, 1203-1215.	0.9	11
276	Linkage analysis in juvenile neuronal ceroid lipofuscinosis. <i>American Journal of Medical Genetics Part A</i> , 1992, 42, 542-545.	2.4	10
277	Virus vectors for gene delivery to the nervous system. <i>Restorative Neurology and Neuroscience</i> , 1995, 8, 21-34.	0.4	10
278	GlioM&M: Web-based tool for studying circulating and infiltrating monocytes and macrophages in glioma. <i>Scientific Reports</i> , 2020, 10, 9898.	1.6	10
279	AAV9 transduction mediated by systemic delivery of vector via retro-orbital injection in newborn, neonatal and juvenile mice. <i>Experimental Animals</i> , 2021, 70, 450-458.	0.7	10
280	Exclusion of p75NGFR and other candidate genes in a family with hereditary sensory neuropathy Type II. <i>Pain</i> , 1996, 67, 135-139.	2.0	9
281	Versatile Role of Rab27a in Glioma: Effects on Release of Extracellular Vesicles, Cell Viability, and Tumor Progression. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 554649.	1.6	9
282	Exogenous loading of extracellular vesicles, virus-like particles, and lentiviral vectors with supercharged proteins. <i>Communications Biology</i> , 2022, 5, 485.	2.0	9
283	Distinct forms of monoamine oxidase expressed in hepatoma and HeLa cells in culture. <i>Biochemical Pharmacology</i> , 1979, 28, 525-528.	2.0	8
284	567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease. <i>Molecular Therapy</i> , 2016, 24, S226-S227.	3.7	8
285	Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 1-12.	2.3	8
286	Differences in monoamine oxidase activity between cultured noradrenergic and cholinergic sympathetic neurons. <i>Developmental Biology</i> , 1987, 120, 305-308.	0.9	7
287	Isolation of the mRNA encoding rat liver catechol-O-methyltransferase. <i>Biochemical and Biophysical Research Communications</i> , 1989, 158, 776-782.	1.0	7
288	Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts. <i>Scientific Reports</i> , 2018, 8, 2324.	1.6	7

#	ARTICLE	IF	CITATIONS
289	Oncogenes in neural tumors. Trends in Neurosciences, 1986, 9, 150-155.	4.2	6
290	Dopamine beta-hydroxylase gene excluded in four subtypes of hereditary dystonia. Human Genetics, 1991, 87, 311-316.	1.8	6
291	Cell-mediated delivery of neurotrophic factors and neuroprotection in the neostriatum and substantia nigra. Restorative Neurology and Neuroscience, 1995, 8, 59-61.	0.4	6
292	Peripherin gene is linked to keratin 18 gene on human chromosome 12. Somatic Cell and Molecular Genetics, 1995, 21, 83-88.	0.7	6
293	TorsinA and early-onset torsion dystonia. Advances in Neurology, 2004, 94, 87-93.	0.8	6
294	Models for Inherited Susceptibility to Cancer in the Nervous System: A Molecular-Genetic Approach to Neurofibromatosis. Developmental Neuroscience, 1987, 9, 144-153.	1.0	5
295	Magnetic Resonance Imaging and Characterization of Spontaneous Lesions in a Transgenic Mouse Model of Tuberous Sclerosis as a Model for Endothelial Cell-Based Transgene Delivery. Human Gene Therapy, 2005, 16, 1367-1376.	1.4	5
296	Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype. , 2000, 48, 65.		5
297	Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy - Methods and Clinical Development, 2022, , .	1.8	5
298	Effect of riboflavin on monoamine oxidase activity in cultured neuroblastoma cells. Cellular and Molecular Neurobiology, 1981, 1, 351-359.	1.7	4
299	Healing Genes in the Nervous System. Neuron, 2010, 68, 178-181.	3.8	4
300	Dopa-Responsive Dystonia: Functional Analysis of Single Nucleotide Substitutions within the 5â€™™ Untranslated GCH1 Region. PLoS ONE, 2013, 8, e76975.	1.1	4
301	Mutant human torsinA, responsible for early-onset dystonia, dominantly suppresses GTPCH expression, dopamine levels and locomotion in <i>Drosophila melanogaster</i> . Biology Open, 2015, 4, 585-595.	0.6	4
302	Expression of monoamine oxidase A and B activities in mouse cybrids and hybrids. Life Sciences, 1981, 28, 425-432.	2.0	3
303	Biological Gene-Product Delivery to the Brain: A Protocol for Retroviral Gene Transfer into Cultured Cells and Intracerebral Transplantation. Methods, 1993, 3, 63-68.	0.5	3
304	Refocus the Recombinant DNA Advisory Committee. Nature Medicine, 2012, 18, 1007-1007.	15.2	3
305	Do DNA rearrangements occur in neuronal development? Clues from an inherited human disease. Trends in Neurosciences, 1983, 6, 444-446.	4.2	2
306	TorsinA and DYT1 early-onset dystonia. Future Neurology, 2008, 3, 61-72.	0.9	2

#	ARTICLE	IF	CITATIONS
307	Genetic Evaluation in Primary Dystonia. Medical Psychiatry, 2006, , 21-44.	0.2	2
308	Herpes Virus Vectors. , 2002, , 201-233.		1
309	438. Targeting HSV-1 Virions for Specific Binding to Epidermal Growth Factor Receptor-VIII on Tumor Cells. Molecular Therapy, 2006, 13, S168.	3.7	1
310	Tannous et al. Respond:. Molecular Therapy, 2009, 17, 1311-1312.	3.7	1
311	The ASGCT in 2012: Charting a Path to Bring Novel Biologic Therapies to the Clinic. Molecular Therapy, 2012, 20, 1289-1290.	3.7	1
312	TMIC-28. GLIOBLASTOMA EXPLOITS CELL SURFACE GLYCOSYLATION-MEDIATED IMMUNE REGULATORY CIRCUITS FOR IMMUNE ESCAPE. Neuro-Oncology, 2018, 20, vi262-vi262.	0.6	1
313	Application of HSV-1 Vectors to the Treatment of Cancer. , 0, , 19-53.		1
314	DYT1 Transgenic Mouse. , 2005, , 287-292.		1
315	Biotinylated ?-Nerve Growth Factor Binds to PC12 Cells. Annals of the New York Academy of Sciences, 1986, 463, 214-216.	1.8	0
316	956. Imaging of Radiation-Inducible Promoters Using a Naturally Secreted Luciferase from the Marine Copepod <i>Gaussia princeps</i> . Molecular Therapy, 2006, 13, S369.	3.7	0
317	635. Mechanisms of Caspase-1 Mediated Schwannoma Regression. Molecular Therapy, 2015, 23, S252.	3.7	0
318	Long-term therapeutic efficacy of intravenous AAV-mediated hamartin replacement in mouse model of tuberous sclerosis type 1. IBRO Reports, 2019, 6, S504.	0.3	0
319	OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, ii7-ii7.	0.4	0